Have a feature idea you'd love to see implemented?
Let us know!
VERV Verve Therapeutics Inc
Price (delayed)
$4.6
Market cap
$389.45M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$2.46
Enterprise value
$297.23M
Highlights
Verve Therapeutics's EPS has increased by 20% YoY and by 5% QoQ
Verve Therapeutics's revenue has increased by 18% from the previous quarter
Verve Therapeutics's equity has increased by 10% YoY but it has decreased by 7% from the previous quarter
The quick ratio has declined by 11% since the previous quarter and by 10% year-on-year
VERV's debt is up by 7% year-on-year
Key stats
What are the main financial stats of VERV
Market
Valuations
Earnings
Shares outstanding
84.66M
Market cap
$389.45M
Enterprise value
$297.23M
Price to earnings (P/E)
N/A
Price to book (P/B)
0.77
Price to sales (P/S)
15.96
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
12.18
Revenue
$24.4M
EBIT
-$196.72M
EBITDA
-$183.03M
Free cash flow
-$162.06M
Per share
Balance sheet
Liquidity
EPS
-$2.46
Free cash flow per share
-$1.91
Book value per share
$6.01
Revenue per share
$0.29
TBVPS
$7.84
Total assets
$663.91M
Total liabilities
$155.36M
Debt
$71.26M
Equity
$508.55M
Working capital
$513.82M
Debt to equity
0.14
Current ratio
13.05
Quick ratio
12.84
Net debt/EBITDA
0.5
Margins
Efficiency
Dividend
EBITDA margin
-750.2%
Gross margin
100%
Net margin
-807.6%
Operating margin
-928.6%
Return on assets
-27.7%
Return on equity
-35.2%
Return on invested capital
-34%
Return on capital employed
-31.7%
Return on sales
-806.4%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
VERV stock price
How has the Verve Therapeutics stock price performed over time
Intraday
1.1%
1 week
-14.5%
1 month
-17.12%
1 year
-59.79%
YTD
-67%
QTD
-4.96%
Financial performance
How have Verve Therapeutics's revenue and profit performed over time
Revenue
$24.4M
Gross profit
$24.4M
Operating income
-$226.54M
Net income
-$197.03M
Gross margin
100%
Net margin
-807.6%
VERV's net margin has surged by 68% year-on-year and by 13% since the previous quarter
The operating margin has soared by 67% YoY and by 14% from the previous quarter
Verve Therapeutics's revenue has increased by 18% from the previous quarter
VERV's gross profit is up by 18% since the previous quarter
Growth
What is Verve Therapeutics's growth rate over time
Valuation
What is Verve Therapeutics stock price valuation
P/E
N/A
P/B
0.77
P/S
15.96
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
12.18
Verve Therapeutics's EPS has increased by 20% YoY and by 5% QoQ
The P/B is 36% below the last 4 quarters average of 1.2
Verve Therapeutics's equity has increased by 10% YoY but it has decreased by 7% from the previous quarter
The price to sales (P/S) is 65% less than the last 4 quarters average of 45.4
Verve Therapeutics's revenue has increased by 18% from the previous quarter
Efficiency
How efficient is Verve Therapeutics business performance
Verve Therapeutics's return on sales has surged by 68% YoY and by 13% QoQ
The ROA has grown by 10% YoY
VERV's ROE is up by 9% YoY
VERV's return on invested capital is down by 3.7% since the previous quarter
Dividends
What is VERV's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for VERV.
Financial health
How did Verve Therapeutics financials performed over time
The current ratio has declined by 11% since the previous quarter and by 9% year-on-year
The quick ratio has declined by 11% since the previous quarter and by 10% year-on-year
VERV's debt is 86% smaller than its equity
Verve Therapeutics's equity has increased by 10% YoY but it has decreased by 7% from the previous quarter
VERV's debt to equity is up by 8% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.